Neovacs Scientific Advisory Board Endorses Company's Updated IFNa-Kinoid Development Plan
March 04, 2015 02:15 ET
|
Neovacs, Inc.
IFNα-Kinoid program to target Systemic Lupus Erythematosus (SLE) as first indication
Important pipeline extension to dermatomyositis, an orphan condition linked to IFNα
SAB...
Neovacs to Present at BIO CEO & Investor Conference
January 20, 2015 11:40 ET
|
Neovacs, Inc.
PARIS, Jan. 20, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today that the Company will be...
Neovacs Announces Top Line Phase IIb Clinical Trial Results of TNF-Kinoid in Rheumatoid Arthritis and Update on Clinical Programs
December 16, 2014 02:00 ET
|
Neovacs, Inc.
Phase IIb clinical trial of TNF-Kinoid in Rheumatoid Arthritis confirmed the good safety profile as well as antibody production, but failed to meet efficacy endpoints. Further evaluation is...